FDA Has Documented Blindness, Tumors, and Infections from Unregulated Stem Cell Clinics: The Claim Is True

The claim is that the FDA has documented serious complications — specifically blindness, tumor formation, and infections — from under-regulated stem cell applications. The verdict is true, and the documentation trail runs from peer-reviewed medical journals straight through to federal court.

The blindness cases are the sharpest evidence. In 2017, Kuriyan et al. published in the New England Journal of Medicine the cases of three patients treated at US Stem Cell Clinic in Florida with intravitreal injections of autologous adipose-derived stem cells. All three suffered severe bilateral vision loss, including retinal detachment and permanent blindness. The FDA issued a formal warning letter to that same clinic on August 28, 2017, citing unapproved biological products and significant manufacturing violations, explicitly linking the clinic to those three patients. This is not an allegation — it is a documented federal enforcement action tied to named, published cases.

Tumor formation and infections are equally well-documented. A 2010 NEJM case report by Thirabanjasak et al. described a patient who developed a renal mass — an angiomyeloproliferative lesion — after receiving stem cell injections, a direct instance of tumor formation from unregulated treatment. The FDA's own 2019 consumer safety communication explicitly listed adverse events including spinal tumors, bacterial infections, and fungal infections reported to the agency from unproven stem cell therapies. A 2018 analysis in Cell Stem Cell by Bauer et al., drawing on FDA adverse event reports and published case series, identified at least 35 serious adverse events from unproven stem cell interventions in the U.S. between 2004 and 2017, spanning infections, tumor formation, and neurological complications.

The strongest version of a counterargument would be that these are isolated cases and that the total number of affected patients is unknown. That is a fair point — underreporting to the FDA's adverse event system is a known limitation, and the true national scope is almost certainly larger than what is captured in the record. But that caveat actually strengthens the concern rather than undermining it: the documented cases represent a floor, not a ceiling. What is not in dispute is that the FDA itself, in a 2019 joint statement from Commissioner Scott Gottlieb and CBER Director Peter Marks, confirmed all three complication categories and announced stepped-up enforcement against approximately 100 unregistered stem cell clinics. The FDA subsequently won a federal court injunction against US Stem Cell Clinic in 2019.

What is genuinely true in any skeptical reading is that legitimate, FDA-approved stem cell therapies — such as bone marrow transplants for blood cancers — have strong safety records. The documented harms come specifically from clinics operating outside the regulatory framework, offering unapproved products for conditions ranging from arthritis to autism. The distinction between regulated and unregulated is the entire point of the claim, and the evidence supports it precisely.

The manipulation pattern to watch for runs in the opposite direction: stem cell clinic marketing that cites the existence of legitimate therapies to imply their own unproven treatments are similarly vetted. If a clinic cannot point to an FDA Investigational New Drug application or an approved Biologics License Application, the treatments it offers are not regulated in the way the marketing implies — and the FDA's own enforcement record shows what that gap can cost patients.